8-K: Y-mAbs Q2 Results & $412M SERB Acquisition

Y-mAbs Therapeutics reports Q2 2025 financial results, exceeding revenue guidance, alongside a definitive agreement for SERB Pharmaceuticals to acquire the company for $412.0 million.

Summary

• Total revenues for the second quarter of 2025 were $19.5 million, exceeding the company's guidance range of $17 million to $19 million.
• Total revenues decreased by 14% to $19.5 million in Q2 2025 from $22.8 million in Q2 2024.
• Total DANYELZA net product revenues for Q2 2025 were $19.0 million, a 17% decrease from $22.8 million in Q2 2024.
• U.S. DANYELZA net product revenues for Q2 2025 were $14.3 million, a 6% decrease from the same period in 2024, driven by declining patient volume due to enrollments in clinical studies and competition.
• Ex-U.S. DANYELZA net product revenues for Q2 2025 were $4.7 million, a decrease from Q2 2024 primarily due to the absence of stocking orders from Western Europe and Eastern Asia, partially offset by a $2.0 million increase in Western Asia from a named patient program in Turkey.
• Net loss for Q2 2025 was $3.2 million, or ($0.07) per basic and diluted share, a significant improvement from a net loss of $9.2 million, or ($0.21) per share, in Q2 2024.
• The decrease in net loss was primarily driven by $3.8 million in litigation settlements in Q2 2024 and $2.0 million of foreign currency transaction gains in Q2 2025.
• As of June 30, 2025, cash and cash equivalents were $62.3 million.
• Y-mAbs has entered into a definitive agreement with SERB Pharmaceuticals for SERB to acquire Y-mAbs in a transaction at an equity value of $412.0 million.
• Under the merger agreement, SERB is obligated to commence a tender offer by August 19, 2025, to purchase all outstanding shares of Y-mAbs for $8.60 per share in cash.
• The $8.60 per share price represents a 105% premium to Y-mAbs' closing share price on August 4, 2025.
• The transaction was unanimously approved by the Y-mAbs Board of Directors and is expected to close by the fourth quarter of 2025.

Sentiment

Score: 9

Explanation: The definitive agreement for SERB Pharmaceuticals to acquire Y-mAbs at a 105% premium to the recent share price is a highly positive development for shareholders, providing immediate and substantial value. While Q2 revenues saw a decline, the net loss improved, and revenues still exceeded the company's own guidance. The acquisition provides a clear exit strategy and valuation for the company's assets.

Positives

• Total revenues of $19.5 million for Q2 2025 exceeded the company's guidance range of $17 million to $19 million.
• Net loss significantly decreased to $3.2 million in Q2 2025 from $9.2 million in Q2 2024, driven by prior litigation settlements and foreign currency gains.
• SERB Pharmaceuticals agreed to acquire Y-mAbs for $412.0 million, or $8.60 per share, representing a 105% premium to the closing share price on August 4, 2025.
• The acquisition was unanimously approved by the Y-mAbs Board of Directors, indicating strong internal support for the transaction.

Negatives

• Total revenues for Q2 2025 decreased by 14% to $19.5 million from $22.8 million in Q2 2024.
• Total DANYELZA net product revenues for Q2 2025 decreased by 17% to $19.0 million from $22.8 million in Q2 2024.
• U.S. DANYELZA net product revenues decreased by 6% due to declining patient volume from clinical studies and competition.
• Ex-U.S. DANYELZA net product revenues decreased due to the absence of stocking orders from Western Europe and Eastern Asia in Q2 2025, which were present in Q2 2024.
• Gross margin decreased for the six months ended June 30, 2025, to 86% from 88% in the prior year, primarily due to increased cost of production and lower product sales to Western Europe, a region that typically yields higher gross margins.

Risks

• Uncertainties regarding the timing of the tender offer for the acquisition.
• Uncertainties regarding the number of Y-mAbs stockholders who will tender their stock in the offer.
• The possibility that competing offers or acquisition proposals will be made.
• The possibility that various closing conditions for the transaction may not be satisfied or waived, including governmental entity approval (e.g., Hart-Scott-Rodino Antitrust Improvements Act).
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Merger Agreement.
• The possibility that the transaction does not close.
• Risks related to the parties' ability to realize the anticipated benefits of the proposed transaction, including the possibility that expected benefits will not be realized or will not be realized within the expected time period, or that integration may be more difficult, time-consuming, or costly than expected.
• Negative effects of this announcement or the consummation of the proposed transaction on the market price of Y-mAbs common stock and/or Y-mAbs operating results.
• Significant transaction costs associated with the acquisition.
• Unknown or inestimable liabilities that may arise.
• The risk of litigation and/or regulatory actions related to the proposed transaction.
• SERB's ability to fund the proposed transaction.
• Challenges in obtaining and maintaining adequate coverage and reimbursement for products.
• The time-consuming and uncertain regulatory approval process for pharmaceutical products.
• The costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients.
• Global economic, financial, and healthcare system disruptions and their current and potential future negative impacts to business operations and financial results.
• The sufficiency of the parties' cash flows and capital resources.
• The ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting, and other provisions and estimates.

Future Outlook

The primary future outlook for Y-mAbs Therapeutics is its pending acquisition by SERB Pharmaceuticals, which is expected to close by the fourth quarter of 2025. This transaction is subject to the completion of a tender offer and other customary closing conditions, including regulatory approvals. Due to this pending transaction, Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results, indicating a shift in focus towards the acquisition's completion.

Management Comments

• Y-mAbs will not be holding a webcast and conference call to discuss its second quarter 2025 results in light of the pending transaction.

Industry Context

This announcement reflects a trend of consolidation in the biopharmaceutical sector, where larger specialty pharmaceutical companies like SERB acquire smaller, commercial-stage firms with approved products (like DANYELZA) and promising pipelines (SADA PRIT, Y-BiClone platform) to expand their portfolios and market reach. The significant premium paid suggests confidence in Y-mAbs' assets despite recent revenue declines, potentially indicating a strategic fit or belief in untapped market potential for DANYELZA or pipeline assets under SERB's broader commercial infrastructure. This acquisition could allow SERB to strengthen its oncology portfolio and leverage Y-mAbs' specialized expertise in radioimmunotherapy and antibody-based therapeutics.

Stakeholder Impact

• Shareholders: Highly positive impact due to the 105% premium offered in the acquisition, providing immediate liquidity and a significant return on investment.
• Employees: Potential for integration challenges or changes in roles/employment under SERB ownership, though specific details are not provided.
• Customers (Patients/Healthcare Providers): Continued access to DANYELZA under SERB, potentially with broader reach or different commercial strategies.
• Suppliers/Business Partners: Existing relationships may be re-evaluated or integrated under SERB's operational structure.

Next Steps

• SERB is obligated to commence a tender offer by August 19, 2025.
• Completion of the tender offer, requiring a majority of outstanding Y-mAbs shares to be tendered.
• Satisfaction of customary closing conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
• The transaction is expected to close by the fourth quarter of 2025.

Key Dates

Recommendation

The announced acquisition of Y-mAbs by SERB Pharmaceuticals at $8.60 per share represents a 105% premium to the closing share price on August 4, 2025. This creates a significant arbitrage opportunity for investors to buy shares at the current market price (likely below $8.60) and tender them in the upcoming offer to realize the premium. The transaction has been unanimously approved by Y-mAbs' Board and is expected to close by Q4 2025, subject to customary conditions. This is a strong buy recommendation for a short-term, event-driven strategy to capture the acquisition premium.

Keywords

Biopharmaceutical, Cancer Treatment, Radioimmunotherapy, Antibody-based therapeutics, DANYELZA, Neuroblastoma, Acquisition, Merger, Financial Results, Q2 2025, SEC Filing, Y-mAbs Therapeutics, SERB Pharmaceuticals, Tender Offer, Oncology